Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients

NCT01638676 is registered in ClinicalTrials.gov with University of Louisville as lead sponsor.

NCT NCT01638676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01638676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients
Lead sponsor
University of Louisville
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 31, 2012
Completion date
June 30, 2027
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma